Cargando…
Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials
BACKGROUND: Patients, who discontinue early, do not benefit from phase I/II clinical trials (early-phase clinical trials (EPCT)). In this study, associations between objective smartphone measurements of physical activity and fitness and early trial discontinuation in patients with cancer participati...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163675/ https://www.ncbi.nlm.nih.gov/pubmed/33236210 http://dx.doi.org/10.1007/s00520-020-05902-2 |
_version_ | 1783700951968776192 |
---|---|
author | Douma, Joeri A. J. Zweegman, Sonja Alberts, Mieke Kruyswijk, Sandy van de Donk, Niels C. W. J. van Linde, Myra Buffart, Laurien M. Verheul, Henk M. W. |
author_facet | Douma, Joeri A. J. Zweegman, Sonja Alberts, Mieke Kruyswijk, Sandy van de Donk, Niels C. W. J. van Linde, Myra Buffart, Laurien M. Verheul, Henk M. W. |
author_sort | Douma, Joeri A. J. |
collection | PubMed |
description | BACKGROUND: Patients, who discontinue early, do not benefit from phase I/II clinical trials (early-phase clinical trials (EPCT)). In this study, associations between objective smartphone measurements of physical activity and fitness and early trial discontinuation in patients with cancer participating in EPCT were investigated. METHODS: Before start of treatment, physical activity (steps/day) and physical fitness (meters walked in 6 min) were measured with a smartphone, and patient-reported physical function (PRO-PF) was assessed (EORTC QLQ-C30-PF). Early trial discontinuation was defined as discontinuation ≤ 28 days. Univariable logistic regression analyses were performed to study associations of physical activity, fitness, and function with early trial discontinuation. Optimal cutoff values of physical activity and fitness were assessed with ROCs, based on positive predictive values (PPV). RESULTS: Median (interquartile range (IQR)) step count was 4263 (2548–6897) steps/day, mean ± standard deviation 6-min walking distance was 477 ± 120 m and median (IQR) PRO-PF score was 83 (67–95) points. Fourteen patients (12%) discontinued the trial early. Smartphone measurements of physical activity in units of 100 steps per day (odds ratio (OR) = 0.96, 95% CI = 0.94–0.99, p = 0.01), physical fitness (OR = 0.99, 95% CI = 0.98–0.99, p < 0.01), and PRO-PF (OR = 0.97, 95% CI = 0.94–1.00, p = 0.03) were associated with early trial discontinuation. Optimal cutoff values were < 900 steps for physical activity and < 285 m for physical fitness. PPV for early trial discontinuation was 100% in patients who walked both < 1500 steps per day and < 300 m in 6 min. CONCLUSIONS: Objective smartphone measurements of physical activity and fitness are associated with early trial discontinuation. However, cutoff values should be externally validated in a larger cohort before implementation in clinical practice. |
format | Online Article Text |
id | pubmed-8163675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-81636752021-06-17 Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials Douma, Joeri A. J. Zweegman, Sonja Alberts, Mieke Kruyswijk, Sandy van de Donk, Niels C. W. J. van Linde, Myra Buffart, Laurien M. Verheul, Henk M. W. Support Care Cancer Original Article BACKGROUND: Patients, who discontinue early, do not benefit from phase I/II clinical trials (early-phase clinical trials (EPCT)). In this study, associations between objective smartphone measurements of physical activity and fitness and early trial discontinuation in patients with cancer participating in EPCT were investigated. METHODS: Before start of treatment, physical activity (steps/day) and physical fitness (meters walked in 6 min) were measured with a smartphone, and patient-reported physical function (PRO-PF) was assessed (EORTC QLQ-C30-PF). Early trial discontinuation was defined as discontinuation ≤ 28 days. Univariable logistic regression analyses were performed to study associations of physical activity, fitness, and function with early trial discontinuation. Optimal cutoff values of physical activity and fitness were assessed with ROCs, based on positive predictive values (PPV). RESULTS: Median (interquartile range (IQR)) step count was 4263 (2548–6897) steps/day, mean ± standard deviation 6-min walking distance was 477 ± 120 m and median (IQR) PRO-PF score was 83 (67–95) points. Fourteen patients (12%) discontinued the trial early. Smartphone measurements of physical activity in units of 100 steps per day (odds ratio (OR) = 0.96, 95% CI = 0.94–0.99, p = 0.01), physical fitness (OR = 0.99, 95% CI = 0.98–0.99, p < 0.01), and PRO-PF (OR = 0.97, 95% CI = 0.94–1.00, p = 0.03) were associated with early trial discontinuation. Optimal cutoff values were < 900 steps for physical activity and < 285 m for physical fitness. PPV for early trial discontinuation was 100% in patients who walked both < 1500 steps per day and < 300 m in 6 min. CONCLUSIONS: Objective smartphone measurements of physical activity and fitness are associated with early trial discontinuation. However, cutoff values should be externally validated in a larger cohort before implementation in clinical practice. Springer Berlin Heidelberg 2020-11-24 2021 /pmc/articles/PMC8163675/ /pubmed/33236210 http://dx.doi.org/10.1007/s00520-020-05902-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Douma, Joeri A. J. Zweegman, Sonja Alberts, Mieke Kruyswijk, Sandy van de Donk, Niels C. W. J. van Linde, Myra Buffart, Laurien M. Verheul, Henk M. W. Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials |
title | Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials |
title_full | Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials |
title_fullStr | Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials |
title_full_unstemmed | Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials |
title_short | Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials |
title_sort | smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase i/ii clinical trials |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163675/ https://www.ncbi.nlm.nih.gov/pubmed/33236210 http://dx.doi.org/10.1007/s00520-020-05902-2 |
work_keys_str_mv | AT doumajoeriaj smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT zweegmansonja smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT albertsmieke smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT kruyswijksandy smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT vandedonknielscwj smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT vanlindemyra smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT buffartlaurienm smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials AT verheulhenkmw smartphonemeasurementsofphysicalactivityandfitnessareassociatedwithearlytrialdiscontinuationofpatientsinhematooncologyphaseiiiclinicaltrials |